No Data
Express News | Relay Therapeutics Inc - FDA Recommends Nda for Fgfr2-Driven Cca Followed by Supplemental Nda
Express News | Relay Therapeutics Inc - to Receive up to $500 Million in Payments
Express News | Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in Fgfr2-Driven Cholangiocarcinoma and Other Solid Tumors
Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors
Down -23.95% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround
H.C. Wainwright Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $20
No Data